Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-612.17%
operating margin TTM
-697.81%
revenue TTM
109.64 Million
revenue per share TTM
1.34$
valuation ratios | |
|---|---|
| pe ratio | -25.93 |
| peg ratio | 1.74 |
| price to book ratio | 5.31 |
| price to sales ratio | 132.88 |
| enterprise value multiple | -22.55 |
| price fair value | 5.31 |
profitability ratios | |
|---|---|
| gross profit margin | 100.0% |
| operating profit margin | -697.81% |
| pretax profit margin | -612.6% |
| net profit margin | -612.17% |
| return on assets | -18.88% |
| return on equity | -25.02% |
| return on capital employed | -22.36% |
liquidity ratios | |
|---|---|
| current ratio | 10.81 |
| quick ratio | 10.81 |
| cash ratio | 2.30 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 0.00 |
| days of payables outstanding | 0.00 |
| cash conversion cycle | 0.00 |
| receivables turnover | 0.00 |
| payables turnover | 0.00 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.05 |
| debt equity ratio | 0.05 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.05 |
| interest coverage | -1,508.94 |
| cash flow to debt ratio | -3.01 |
cash flow ratios | |
|---|---|
| free cash flow per share | -2.50 |
| cash per share | 6.67 |
| operating cash flow per share | -2.49 |
| free cash flow operating cash flow ratio | 1.01 |
| cash flow coverage ratios | -3.01 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -171.31 |
Frequently Asked Questions
When was the last time Kymera Therapeutics, Inc. (NASDAQ:KYMR) reported earnings?
Kymera Therapeutics, Inc. (KYMR) published its most recent earnings results on 30-04-2026.
What is Kymera Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Kymera Therapeutics, Inc. (NASDAQ:KYMR)'s trailing twelve months ROE is -25.02%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Kymera Therapeutics, Inc. (KYMR) currently has a ROA of -18.88%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did KYMR's net profit margin stand at?
KYMR reported a profit margin of -612.17% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is KYMR's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 10.81 in the most recent quarter. The quick ratio stood at 10.81, with a Debt/Eq ratio of 0.05.